August 8, 2013 (San Diego) – There have been many breakthroughs recently in the study of adult (non-embryonic) stem cells. But the national media has all but ignored them. Most news outlets still seem to prefer perpetuating the tired notion that all adult stem cell researchers are cons and all patients who enroll in adult stem cell clinical trials are fools. That's no longer the case.

Yes, there are still unethical players in this sector who take advantage of ailing, desperate patients willing to try anything. And yes, this is a relatively new field about which there is still much to learn. But a number of reputable companies that specialize in this research, including Medistem and Cytori Therapeutics, already have FDA-approved trials under way or in the pipeline for a variety of health conditions.

November 8, 2012 --  (San Diego’s East County) – ECM World Watch helps you be an informed citizen about important issues globally and nationally. As part of our commitment to reflecting all voices and views, we include links to a wide variety of news sources representing a broad spectrum of political, religious, and social views. Top world and U.S. headlines include:

U.S.

• Obama makes history, again (CNN)
• After election, overtures from Republicans on debt (Washington Post)
• House Speaker says he’ll consider tax increase (SF Gate)
• Big gains for women in 2012 (CNN)
• Obama to weigh energy boom, climate change in second term (Reuters)
• After Romney losses, GOP soul searching begins (CBS)
• Hope and change part II (NY Times opinion)
• Marijuana legalization victories could be short-lived
• New York City crime down by a third in wake of superstorm  (Reuters)
• Study: Stem cells from strangers can repair hearts (Sacramento Bee) 

WORLD

• Russia set to redefine treason, sparking fears (NPR)
• Insight: Putin's Russia - more fragile than it looks (Reuters)
• Day of the Dead takes on new meaning for families of Mexico's disappeared (Christian Science Monitor)
• Islamists protest in Cairo, call for Sharia law (Jerusalem Post)